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Head and neck/oral cancer (HNOC) is a devastating disease. Despite advances in diagnosis and treatment, mortality rates have not
improved signiﬁcantly over the past three decades. Improvement in patient survival requires a better understanding of the disease
progression so that HNOC can be detected early in the disease process and targeted therapeutic interventions can be deployed.
Accumulating evidence suggests that microRNAs play important roles in many human cancers. They are pivotal regulators of
diverse cellular processes including proliferation, diﬀerentiation, apoptosis, survival, motility, and morphogenesis. MicroRNA
expression patterns may become powerful biomarkers for diagnosis and prognosis of HNOC. In addition, microRNA therapy
could be a novel strategy for HNOC prevention and therapeutics. Recent advances in microRNA expression proﬁling have led to a
betterunderstandingofthecancerpathogenesis.Inthisreview,wewillsurveyrecenttechnologicaladvancesinmicroRNAproﬁling
and their applications in deﬁning microRNA markers/targets for cancer prediction, diagnostics, treatment, and prognostics.
MicroRNA alterations that consistently identiﬁed in HNOC will be discussed, such as upregulation of miR-21, miR-31, miR-
155, and downregulation of miR-26b, miR-107, miR-133b, miR-138, and miR-139.
Copyright © 2009 Xiqiang Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
1.1. Head and Neck/Oral Cancer. Head and neck/oral cancer
(HNOC) is the sixth most common cancer worldwide
accounting for 4% of cancers in men and 2% of cancers in
women [1]. In some parts of the world, including Southern
ChinaandtheIndiansubcontinent,HNOCisamajorcancer
problem.IntheUS,onepatientdiesfromHNOCeveryhour.
HNOC is one of the undertreated and understudied diseases.
According to American Cancer Society—Cancer Statistics
[2–6], the new cases for HNOC increased approximately
25% during the past 5 years, where the overall new cancer
cases only increased about 5% in the same period (Table 1).
More strikingly, the death associated with HNOC increased
by 5% during the past 5 years, while death associated
with all cancers stayed the same. This represents a major
health problem, and may be linked to suboptimal treatment
outcomes and clinical decision making.
O v e r9 0 %o fH N O Ca r eo r a ls q u a m o u sc e l lc a r c i n o m a
(OSCC), carcinomas arising from the epithelium lining of
the oral cavity. The initiation and progression of OSCC
is a complex multistep process that entails a progressive
acquisition of genetic and epigenetic alterations. HNOC has
traditionally been causally associated with heavy smoking
and alcohol abuse [7]. Of these, tobacco smoking is well
established as a dominant risk factor for OSCC, and
this risk is correlated with the intensity and duration of
smoking. Nevertheless, the increased incidence of HNOC
in nonsmokers and nondrinking patients in recent years
suggests that other environmental, immunologic, or genetic
factors also contribute to the pathogenesis of HNOC [8].
Human papillomavirus (HPV) is the major etiologic factor
in the development of cervical cancer, and has been studied
extensively [9]. Results of recent molecular and epidemi-
ologic studies suggested that HPV is also an important
etiologic factor in a subset of HNOC [10], particularly those2 Comparative and Functional Genomics
Table 1: The changes of head and neck cancer incidence and death for the past 5 years. (Based on ACS: Cancer Statistics 2004, 2005, 2006,
2007, 2008 [2–6])
Year New Cases Deaths
All cancers Head and neck cancer Pharynx cancer All cancers Head and neck cancer Pharynx cancer
2004 1,368,030 28,260 8,250 563,700 7,230 2,070
2005 1,372,910 29,370 8,590 570,280 7,320 2,130
2006 1,399,790 30,990 8,950 564,830 7,430 2,110
2007 1,444,920 34,360 11,800 559,650 7,550 2,180
2008 1,437,180 35,310 12,410 565,650 7,590 2,200
5-yr total 7,022,830 158,290 50,000 2,824,110 37,120 10,690
5-year increase 69,150 7,050 4,160 1,950 360 130
Percent increase 5.1% 24.9% 50.4% 0.3% 5.0% 6.3%
that developed at pharynx sites, such as oropharyngeal and
tonsillar cancers. According to the American Cancer Society:
Cancer Statistics [2–6], the new cases for pharynx cancer
increased over 50% during for the past 5 years, where the
overallnewcancercasesonlyincreasedabout5%inthesame
period (Table 1).
1.2. MicroRNA Biogenesis and Functions. Like most of the
other human cancers, HNOC is a disease involving multistep
dynamic changes in the genome. However, most studies on
the cancer genome have focused most heavily on protein-
coding genes, and our knowledge of alterations of the
noncoding sequences in cancer is largely absent. In the
past several years, the biomedical ﬁelds have manifested
a rapidly expanding interest on a relatively small number
of small genes—microRNAs (miRNAs). MicroRNAs are
newly recognized, noncoding, regulatory RNA molecules,
about 22 nucleotides (nts) in length, and found in all
metazoans studied thus far. It is estimated that the human
genome may have 800–1000 microRNAs [11]. Although they
account for only a very minor fraction of the expressed
genome, microRNAs are pivotal regulators of development
and cellular homeostasis through their control of diverse
cellular processes including proliferation, diﬀerentiation,
apoptosis, survival, motility, and morphogenesis.
The microRNA biogenesis has been investigated exten-
sively. While most of the microRNAs are transcribed by the
R N Ap o l y m e r a s eI It op r o d u c eap r i m a r y - m i c r o R N A( p r i -
microRNA), approximately 20% of human microRNAs are
transcribed by RNA polymerase III. Pri-microRNAs are usu-
ally long nucleotide sequences, and some of them have sev-
eral hundreds to a thousand nucleotides. The pri-microRNA
is spliced and usually capped with a 5
  7-methylguanosine
cap (m7G) and poly-adenylated at the 3
  end, similar to
protein-coding mRNAs. Then, pri-microRNAs form speciﬁc
hairpin-shaped stem-loop secondary structures and enter
a microprocessor complex (500–650kDa) consisting of a
Drosha (a RNase III endonuclease) and an essential cofactor
DGCR8/Pasha (protein containing two double-stranded
RNA binding domains). There they are processed into a
60- to 70-nt pre-microRNA with a 5
  phosphate and a 3
 
2 nt overhang. The pre-microRNAs are then transported
to the cytoplasm by Exportin-5 (Exp5) (a member of the
Ran transport receptor family). Once in the cytoplasm, pre-
microRNAs are further processed to a short double strand
microRNA:microRNA
∗ d u p l e xb yD i c e r ,as e c o n dR N a s eI I I
endonuclease. Finally, the microRNA:microRNA
∗ duplex is
unwound into a mature microRNA and microRNA
∗ by a
helicase. The mature microRNAs are asymmetrically incor-
porated into the RNA-induced silencing complex (RISC)
where they regulate gene expression by mRNA degradation
or translational repression while the microRNA
∗ is quickly
degraded.
However, microRNAs are not involved directly in protein
coding, but are believed to control the expression of more
than one-third of the protein-coding genes in the human
genome [12–14]. Each microRNA can target and regulate
the mRNA transcripts of hundreds of genes downstream.
One microRNA can have multiple target sites in the mRNA
transcript of a downstream gene, while one mRNA can
be targeted by multiple microRNAs. Therefore, microRNAs
contribute a newly recognized level of regulation of gene
expression. As illustrated in Figure 1, the potential mecha-
nisms of microRNA-mediated gene regulation are multifac-
torial and encompass interaction(s) among diﬀerent mech-
anisms. It has been demonstrated that microRNA direct-
target the mRNA and regulate the expression of the target
gene at post-transcriptional levels (e.g., enhance mRNA
degradation and inhibit translation). This cis-regulation
occurs by binding of the ∼21 nucleotide mature microRNA
to an imperfectly matched sequence in the target mRNA.
Following the expression changes of speciﬁc microRNA-
targeted genes (e.g., genes code for transcription factors, and
genes code for RNA regulating proteins), subsequent eﬀects
may alter the levels of other mRNAs (or protein interaction),
and thus microRNA may exert its eﬀects on the expressed
genome through transregulatory mechanism(s).
For more details on microRNA biogenesis, basic func-
tions, and their roles in normal physiology and diseases,
numerous excellent reviews are recommended [15–21].
In the following sections, we survey recent technologi-
cal advances in microRNA proﬁling of tumor cells and
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Figure 1: Potential microRNA regulation mechanisms. The potential mechanisms of microRNA-mediated gene regulation are multifactorial
and encompass interaction(s) among diﬀerent mechanisms. Cis-regulation: microRNA direct targeting the mRNA and regulating the
expression of the target gene at post-transcriptional levels (e.g., enhance mRNA degradation and inhibit translation). It has also been
suggested that microRNA can control gene transcription based on potential mechanisms. Transregulation: Following the expression changes
of microRNA targeted speciﬁc genes (e.g., genes coded for transcription factors, genes coded for RNA regulating proteins, and genes coded
for proteins that will interact with the target protein), subsequent eﬀects may alter the transcription of other gene, levels of other mRNAs,
or interactions among proteins, and thus microRNA may exert its functional eﬀects through transregulatory mechanism(s).
deﬁning microRNA markers/targets for cancer prediction,
diagnostics, treatment and prognostics. We will also identify
potential solutions that may overcome these outstanding
challenges to improve the diagnosis and treatment of cancer.
2. Overview of the Commonly Used MicroRNA
ProﬁlingTechnologies inHNOC Studies
High-throughput microRNA gene expression analysis is a
technical challenge. The short length and uniqueness of each
microRNA render many conventional tools ineﬀective—
very small RNAs are diﬃcult to reliably amplify or label
without introducing bias. Earlier attempts for detection
and identiﬁcation of microRNA included 3 approaches:
hybridization-based methods (e.g., Northern blot), PCR-
based detection, and cloning methods. Based on these ini-
tial approaches, higher-throughput technologies have been
developed to systematically proﬁle microRNA at genome-
wide scale. Here, we provide a review of these technologies
and their utilization in HNOC research (Table 2).
2.1. Hybridization-Based MicroRNA Proﬁling—Microarray.
The hybridization-based microRNA detection methods
include Northern blotting, in situ hybridization, bead-
based ﬂow-cytometry, and microarray. The majority of the
published studies reporting microRNA proﬁling analysis
were performed using diﬀerent microarray technologies.
The diﬀerences in these microarray platforms are mainly
in their probe design, probe immobilization chemistry,
sample labeling, and signal detection methods (see [28]f o r
comprehensive review on array-based microRNA proﬁling).
Typical to the evolution of mRNA microarray platforms
during the early stage of microRNA array development,
most of the arrays were custom made. For example, using
a custom microRNA microarray [29], Tran et al. presented
theﬁrstmicroarray-basedmicroRNAproﬁleofHNOCusing
9 HNOC cell lines [22]. Thirty-three microRNAs in the
array were found to be highly expressed (including let7a,
miR-16, miR-21, and miR-205) and 22 showed low levels
of expression (including miR-342, miR-346, and miR-373
∗)
in all cell lines. However, the drawback of this study is the
lack of inclusion of normal control cell lines, which hinders
the ability to detect relative diﬀerence in speciﬁc microRNA
levels between normal and diseased cells. Nevertheless, this
study provides the largest genome-wide survey of mature
microRNA transcripts in head and neck cancer cell lines at
the time.
With the introduction of several commercially available
microRNA array platforms, the study design and data
analysis became more streamlined. Using GenoExplorerTM
microRNA array from GenoSensor Corporation (Tempe,
Ariz, USA), which contains 646 mature and pre-microRNAs,
Chang et al. screened for altered microRNA expression in
both HNOC primary tissue samples, HNOC cell lines, and
normal control samples [24]. Eight microRNAs were found
by to be upregulated (including mir-21, let-7, 18, 29c, 142-
3p, 155, 146b) and one downregulated (miR-494) in cancer.4 Comparative and Functional Genomics
Table 2: Recently identiﬁed microRNA alterations in HNOC.
Proﬁling study Methods microRNA alterations Functional validation
Tran et al., 2007 [22] Proﬁling
for 261 miRNAs was carried out
on 9 HNOC cell lines. No
normal control was included in
this study.
Microarray
High expression in HNOC: miR-21, miR-23a,
let-7f, miR-205, miR-31, let-7d, miR-221, let-7a,
miR-320, miR-23b, miR-24, let-7c, miR-29b,
miR-30b, miR-15a, miR-22, miR-107, miR-200b,
miR-18, miR-16, miR-15b, miR-200a, miR-27a,
let-7b, miR-28, hcv-miR-US33-1, miR-100,
miR-98, miR-103, miR-125b, miR-361, miR-19a
Low expression in HNOC: has-miR-345,
miR-449, miR-302b, miR-382, miR-373, miR-378,
miR-200c, miR-340, miR-302c, miR-154,
miR-371, miR-127, miR-133a, miR-302d,




Hebert et al., 2007 [23] Proﬁling
for ∼260 miRNAs was carried
out on 3 HNOC cell
linescultured under normoxic
(5% O2) or hypoxic conditions
(1% O2).
Microarray
Induced by hypoxia: miR-572, miR-214, miR-563,
miR-637, miR-98, miR-628, miR-191, miR-210,
miR-31, miR-498, miR-373, miR-19a, miR-148a,





doxorubicin and cisplatin. Suppressed by hypoxia: miR-122a, miR-565,
miR-195, miR-30e-5p, miR-374, miR-19a,
miR-101, miR-424, miR-186, miR-29b, miR-148b,
miR-141, miR-22, miR-331, miR-422b, miR-197
Chang et al., 2008 [24] Proﬁling
for 314 miRNAs was carried out
on 4 HNOC tissue samples (with
4 normal tissues as control).
Concurrently, 4 HNOC cell lines
and a normal oral keratinocyte
cell line were also proﬁled.
Microarray
Upregulated in HNOC: miR-21, let-7, miR-18,
miR-29c, miR-142-3p, miR-155, miR-146b
miR-21: regulates cell growth,
cytochrome C release, and
apoptosis. Downregulated in HNOC: miR-494
Wong et al., 2008 [25, 26]
Proﬁling for 156 miRNAs was
carried out on 4 HNOC of
tongue and 4 paired normal
tissues.
qRT PCR
Upregulated in HNOC: miR-184, miR-34c,
miR-137, miR-372, miR-124a, miR-21, miR-124b,
miR-31, miR-128a, miR-34b, miR-154, miR-197,
miR-132, miR-147, miR-325, miR-181c, 198,








Downregulated in HNOC: miR-133a, miR-99a,
miR-194, miR-133b, miR-219, miR-100,
miR-125b, miR-26b, miR-138, miR-149,
miR-195, miR-107, miR-139.
Kozaki et al., 2008 [27] Proﬁling
for 148 miRNAs was carried out
on 18 HNOC cell lines. One
immortalized oral keratinocyte
l i n ew a su s e da sc o n t r o l .
qRT PCR
Upregulated in HNOC: miR-374, miR-340,
miR-224, miR-10a, miR-140, miR-181a∗,
miR-146a, miR-126, miR-31,m i R - 9 ,m i R - 9 ∗.
miR-137: regulates cell growth
and CDK6 expression.
miR-193a: regulates cell
growth and E2F6 expression.
Downregulated in HNOC: miR-27a, miR-34b,
miR-34c, miR-203, miR-302c∗, miR-23a,
miR-27b, miR-34a, miR-215, miR-299, miR-330,
miR-337, miR-107, miR-133b, miR-138,
miR-139, miR-223, miR-204, miR-370, let-7d,
miR-95, miR-302a, miR-367, let-7g, miR-23b,
miR-128a, miR-148a, miR-155, miR-200c,
miR-302b, miR-368, miR-122a, miR-371, let-7a,
miR-26b, miR-30e-5p, miR-96, miR-125a,
miR-132, miR-200b, miR-199b, miR-296,
miR-373
∗, miR-137, miR-197, miR-193a, let-7e,
miR-30d, miR-331, miR-342, miR-338, miR-199a,
miR-372, miR-184Comparative and Functional Genomics 5
Another example of using commercially available platforms
for proﬁling study was designed to deﬁne the HNOC cell
microRNA expression pattern under hypoxia condition [23].
The Human V7.1C 051017 miRNA array (LC Sciences) was
used in this study, which consists of approximately 260
microRNAs that were deposited in miRBase Version 7.1
(Sanger Institute, UK) at that time. The latest version of
human microRNA array from LC Sciences consists of 856
microRNA (corresponding to Sanger miRBase Version 12.0).
Nevertheless, this study identiﬁed 20 upregulated and 16
downregulated microRNAs in HNOC cells cultured under
hypoxia condition [23].
While the currently available commercial microRNA
arrays make proﬁling studies on microRNA a lot easier for
biomedical research laboratories, several new developments
in the biotech ﬁeld have emerged as potential opportunities
to improve microRNA microarrays. Locked nucleic acid
(LNA) has quickly gain popularity in various biological and
biomedical ﬁelds in the recent years due to its unprecedented
aﬃnity and speciﬁcity to the complementary RNA. LNA
is a conformational RNA analogue that contains at least
one LNA monomer. The unique feature of the unprece-
dented thermal stability between LNAs and their target
R N Am o l e c u l e se n a b l e se ﬃcient visualization of microRNA
for in situ hybridization. In addition, the high metabolic
stability of LNA along with enhanced microRNA recognition
properties suggest that LNA-antimiRs could be an important
tool for novel therapeutic approaches based on cancer-
associated microRNAs. Attempts have also been made to
incorporate LNA-based probes in the design of microarrays
for microRNA proﬁling [30–32], which appears to also
improve the mismatch discrimination. While it has not
been utilized in HNOC studies, this platform has recently
been used in studying several other malignancies, including
chronic myeloid leukemia and breast cancer [33, 34]. A
recent review by Stenvang et al. provided a comprehensive
reviewonrecentprogressinLNA-basedmicroRNAdetection
in cancer [35].
Other attempts to improve the microarray-based
microRNA proﬁling include the introduction of the RNA-
primed array-based Klenow enzyme (RAKE) assay [36]
and the development of modiﬁed RAKE assays [37]. The
RAKE assays are based on the ability of an RNA molecule
to function as a primer for Klenow polymerase extension
when fully base-paired with a single-stranded DNA
molecule. When combined with microarray technology,
RAKE appears to provide better speciﬁcity than other
microarray platforms. It has also been reported that with
this RAKE assay, microRNAs isolated from formalin-ﬁxed
paraﬃn-embedded tissue can be utilized to generate optimal
quality microRNA proﬁles [36, 38], which opens up new
opportunities for analyses of small RNAs from archival
human tissue.
2.2. QRT-PCR-Based MicroRNA Proﬁling. While the
microarray-based proﬁling methods described earlier have
excellent throughput and high coverage, these methods do
not amplify the microRNA and thus often compromise the
Precursor miRNA  RT qPCR
(a)
Mature miRNA  RT qPCR
Primer  TaqMan probe  Stem-loop RT primer
(b)
Figure 2: TaqMan assays for quantifying precursor microRNA and
mature microRNA. (a) TaqMan assay designed to quantify hairpin-
containing microRNA precursors. RT reaction and PCR ampliﬁ-
cation are performed using gene-speciﬁc primers. Quantiﬁcation
is carried out using TaqMan minor groove binder (MGB) probes
that are speciﬁc to the loop portion of the microRNA precursor. (b)
TaqMan assay designed to quantify mature microRNA. This assay
utilizes a target speciﬁc stem-loop, reverse transcription primer
for RT reaction. The stem-loop structure provides speciﬁcity for
only the mature microRNA target and forms a RT primer/mature
microRNA-chimera that extends the 3
  end of the microRNA. The
resulting RT product will be quantiﬁed using standard TaqMan
quantitative real-time PCR method.
sensitivity. Real-time quantitative PCR-based approaches
have unparalleled sensitivity and speciﬁcity. However, it
is technically challenging to amplify and quantify mature
microRNA because the mature microRNA is only around 22
nts, roughly the size of a standard PCR primer. Therefore,
earlier versions of qRT-PCR-based method are usually
quantifying microRNA precursors. For example, a large
panel of TaqMan assays were designed for 222 hairpin-
containing microRNA precursors based on RT and PCR
ampliﬁcationusinggene-speciﬁcprimers,andquantiﬁcation
using TaqMan minor groove binder (MGB) probes that
are speciﬁc to the loop portion of the microRNA precursor
[39]. Using this TaqMan assay panel, the microRNA
precursor expression was proﬁled in 32 human cancer
cell lines, including 5 HNOC cell lines [39]. Interestingly,
unsupervised clustering analysis based on the expression
values of these 222 microRNA precursors was able to cluster
most of the cancer cell lines into tissue-speciﬁc groups. This
suggested that the existence of a tissue-speciﬁc microRNA
expression signature for cancers originated from various
tissues. It should be emphasized that this proﬁle is for the
microRNAprecursorsandnottheactive,maturemicroRNA.
While the relative level of most mature microRNAs may be
predicted based on the level of corresponding precursors,
additional tests will be needed to ensure that the expression
of the mature microRNA is reﬂected by the precursor
expression.
Recently a second generation of TaqMan microRNA
assay has be developed to directly quantify the mature
microRNA. This assay incorporates a target-speciﬁc stem-
loop, reverse transcription primer. The innovative design6 Comparative and Functional Genomics
addresses a fundamental challenge in microRNA quantiﬁ-
cation: the short length of mature microRNAs (∼22nt)
prohibits conventional design of a speciﬁc quantitative real-
time PCR assay. The stem-loop structure provides speciﬁcity
for only the mature microRNA target and forms an RT
primer/mature microRNA-chimera that extends the 3
  end
ofthemicroRNA.TheresultinglongerRTproductpresentsa
template amenable to standard real-time PCR using TaqMan
Assays. These latest qPCR assays are commercially available
(e.g., TaqMan MicroRNA Assay from Applied Biosystems).
These assays can be packed into a convenient, preconﬁgured
micro ﬂuidic card that contains up to 384 unique TaqMan
assays, and compatible with most of the commonly used
qPCR instruments. Using this new TaqMan assay, the
microRNA alterations for HNOC were identiﬁed using
HNOC cell lines (compared to the immortalized human oral
keratinocyte line) [27], and laser microdissected cancer cells
from primary HNOC of tongue (compared to the paired
normal tissues) [25].
2.3. Cloning and Sequencing Based MicroRNA Proﬁling.
This approach is developed by combining aspects of direct
microRNA cloning and serial analysis of gene expression
(SAGE) technology, which lead to its name miRAGE [40].
Similar to traditional cloning approaches, miRAGE starts
with the isolation of 18- to 26-base RNA molecules to
which specialized linkers are ligated, and which are reverse-
transcribed into cDNA. However, subsequent steps, includ-
ing ampliﬁcation of the complex mixture of cDNAs using
PCR, tag puriﬁcation, concatenation, cloning, and sequenc-
ing, have been performed by using SAGE methodology opti-
mizedforsmallRNAspecies.Usingthistechnique,Cummins
et al. were able to perform a large scale experimental analysis
of microRNAs in human colorectal cells [40]. Sequence
analysisof273.966smallRNAtagsledtoidentiﬁcationof200
knownmaturemicroRNAs,133novelmicroRNAcandidates,
and 112 previously uncharacterized microRNA
∗ forms.
SAGE was originally designed to characterize gene
expression proﬁles. It has a potential to be a high-
throughput gene expression proﬁling tool. Over the years,
much improvement has been made to increase sequencing
eﬃciency and reduce input RNA amount requirement [41–
46]. Although it is not as popular as microarrays and qRT-




The elucidation of how global microRNA expression con-
tributes to phenotypic outcomes in cancer is critically
important. On the other hand, it is equally important to
deﬁne the signaling pathways, as well as environmental or
genetic factors that aﬀect microRNA expression. Currently,
most of the microRNA-related studies on cancer are based
on the diﬀerent expression proﬁling of microRNAs, which
lead to the identiﬁcation of many so-called “cancerous”
microRNAs. Recent studies have suggested that microRNA
signatures can be used to classify human cancers with accu-
racy compatible to mRNA signatures [47, 48]. Knockdown
or overexpression of a speciﬁc microRNA allows functional
validation and investigation of the speciﬁc roles of the
microRNA in tumorigenesis. MicroRNAs have been func-
tionally classiﬁed as proto-oncogenes or tumor suppressors
and their aberrant expression has been reported in many
cancer types including bladder cancers [49], breast cancer
[50–52], cervical cancer [53–57], colorectal cancer [58–60],
leukemia [61, 62], liver cancer [63–65], lung cancer [66–
68], lymphoma [69], pancreatic tumors [70], and thyroid
cancer [71]. Dysregulation (e.g., overexpression or loss of
expression) of these “cancerous” microRNAs can contribute
prominently in tumor initiation and progression by elab-
orating an inappropriate cellular program that promotes
uncontrolled proliferation, that favors survival, that inhibits
diﬀerentiation and/or promotes invasive behavior [72, 73].
As illustrated in Table 2,an u m b e ro fs t u d i e sh a v eb e e n
recently carried out aiming for the identiﬁcation of speciﬁc
microRNA alterations in HNOC [22–25, 27]. Among those
microRNAs identiﬁed, 6 of them have been functionally
tested in HNOC to demonstrate their “cancerous” functions.
These include miR-21, miR-184, miR-133a/133b, miR-137,
and miR-193a. MiR-21 is a well-established oncogenic
microRNA which enhances the cell proliferation and sup-
presses apoptosis [24, 74–77]. The upregulation of miR-
2 1h a sb e e no b s e r v e di nb o t hH N O Ct i s s u es a m p l e sa n d
HNOC cell lines [24, 25], as well as many other cancer types.
Functional tests in HNOC cell lines conﬁrmed that miR-21
enhancesthecellproliferationandsuppressesapoptosis[24].
The knowledge on miR-184 and its role on tumorigenesis
are still elusive. Wong et al. suggested that miR-184 acts
as a oncogenic microRNA by inhibiting apoptosis and
inducing proliferation in HNOC [25]. However, a tumor
suppressor function was suggested by a recent study showing
that ectopic expression of miR-184 suppresses Akt signaling
pathway, which is associated with a marked increase in
keratinocyte apoptosis and cell death [78]. More studies
will be needed to resolve this apparent contradiction. While
miR-133a downregulation in HNOC has been reported by
Wong et al. [25], downregulation of miR-133b has been
consistently observed by both Wong and Kozaki studies
[25, 27]. The downregulation of miR-133b has also been
observed in colorectal cancer [59]. In a followup study,
Wong et al. further demonstrated the tumor-suppresser
functions of miR-133a/133b that inhibit proliferation and
induce apoptosis in HNOC cell lines [26]. In addition to
their apparent tumor-suppresser function, miR133a/133b
have also been associated with various functional roles in
cardiomyocytes [79–81], osteoblasts [82], and neurons [83].
It has been suggested that both miR-137 and miR-193a are
silenced by DNA hypermethylation in HNOC [27]. This
epigenetic event has also been observed in glioblastoma for
silencing miR-137 [84]. The ectopic transfection of miR-
137 or miR-193a into OSCC lines lacking their expressions
signiﬁcantlyreducedcellgrowth,withdownregulationofthe
translationofcyclin-dependentkinase6orE2Ftranscription
factor 6, respectively [27]. These observations are consistent
with previous ﬁndings in which tumor-suppressing rolesComparative and Functional Genomics 7
have been suggested for miR-137 in glioblastoma [84]a n d
melanoma [85], and for miR-193a in hepatocarcinoma,
lung epithelial carcinoma, and cervical adenocarcinoma
cell lines [86]. Another functionally validated microRNA
in HNOC is miR-98, which is upregulated under hypoxia
condition [23]. Transfection of pre-miR-98 diminishes high
mobility group A2 (HMGA2) and potentiates resistance to
chemotherapeutic drugs, doxorubicin, and cisplatin [23].
These ﬁndings suggest that miR-98 serves as a key element
in modulating tumors in variable microenvironments.
In addition to those functionally validated microRNAs
described earlier, upregulations of miR-155 and miR-31 in
HNOC have been observed in at least 2 independent studies
we reviewed. MiR-155 has been suggested previously as an
oncogenic microRNA [77]. MiR-155 has also been shown
to infer mammalian innate and adaptive immunity, and
viral infection [87]. The expression of miR-155 is regulated
by transforming growth factor beta/Smad pathway [88],
which is frequently elevated in HNOC [89]. While miR-
31 upregulation has been consistently observed in HNOC
[25, 27], its role in tumorigenesis is not entirely clear. The
upregulation of miR-31 has also been observed in colorectal
cancer [59, 60], hepatocellular carcinoma [65], but reduced
expression of miR-31 was observed in breast cancer [52],and
frequent homozygous deletion of miR-31 gene was reported
in urothelial carcinomas [90].
Also, downregulation of several microRNAs has been
consistently observed in HNOC, including miR-26b, miR-
138, miR-107, miR-139. The role of miR-26b in cancer
is not clear. While downregulation of miR-26b has been
observed in HNOC [25, 27], upregulation of miR-26b has
been observed in bladder cancers [49], and polycythemia
vera platelets [91]. Interestingly, miR-26 family members
have been shown to be induced by hypoxia [92]a n dd o w n -
regulated by exposure to cigarette smoke [93]. It is worth
knowing that Myc oncogene suppresses miR-26a, another
member of the miR-26 family, which inﬂuences cell cycle
progression by targeting the oncogene EZH2 in a murine
lymphoma model [94]. The observation of downregulation
ofmiR-138inHNOCisconsistentwithasimilarobservation
in thyroid cancer, in which the downregulation of miR-138
has also been associated with enhanced telomerase reverse
transcriptase (TERT) expression [71]. In addition, miR-138
appears to play an important role in embryonic develop-
ment, as it is required for cardiac morphogenesis during
embryonic development in a temporal knockdown zebraﬁsh
model [95]. The observed downregulation of miR-107 in
HNOC is consistent with its previously suggested tumor
suppresser function in lung carcinoma cells [68]. However,
signiﬁcant overexpression of miR-107 (and its highly homol-
ogous miR-103) has been observed in pancreatic tumors
[70]. High expression of miR-103/107 was also correlated
with poor survival for patients with esophageal squamous
cell carcinoma [96]. Other interesting observations include
that of downregulation of miR-107 is speciﬁcally associated
with HNF1alpha in hepatocellular tumors [97]. Also, all-
trans-retinoic acid (ATRA) treatment lead to upregulated
miR-107 in acute promyelocytic leukemia cells [98]. While
downregulation of miR-139 has been observed in HNOC
[25, 27], relative little is known of the relationship of miR-
139 and cancer [99]. More studies will be needed to deﬁne
the role of miR-139 in tumorigenesis.
Recently, attempts have also been made to translate
these identiﬁed microRNA alterations in HNOC to clinical
utilities, including a preliminary study testing the feasibility
of using miR-205 as a marker to detect metastatic HNOC
cells in lymphoid tissues [100]. The association between
high miR-211 level and poor prognosis of HNOC has
also been suggested [101]. These data lay the foundation
for additional studies that use microRNA to improve the
diagnosis, prognosis, and staging of HNOC.
4. Conclusion andFutureDirections
Despite advances in diagnosis and treatment, mortality rates
of HNOC have not improved signiﬁcantly over the past three
decades, which points to the immediate need for a better
understanding of this disease. Accumulating evidence sug-
gests that microRNAs play important roles in many human
cancers, including HNOC. They are pivotal regulators of
diverse cellular processes including proliferation, diﬀeren-
tiation, apoptosis, survival, motility, and morphogenesis.
Recent advances in microRNA expression proﬁling have
led to a better understanding of the HNOC pathogenesis.
This will lead to the identiﬁcation of speciﬁc microRNA
expression patterns that may become powerful biomarkers
for diagnosis and prognosis of HNOC. In addition, these
microRNAs may also serve as therapeutic targets for novel
strategies of HNOC prevention and therapeutics.
It is important to notice that HNOCs are groups of
diverse cancers that develop from many diﬀerent anatomic
sites and are associated with diﬀerent risk factors [102],
genetic characteristics [103], and diﬀerent clinical outcomes
[104, 105]. Currently, most of the existing microRNA
proﬁling studies on HNOC include cases from multiple
anatomic sites. It will be ideal to obtain the site-speciﬁc
microRNA signatures for various HNOCs, which should
lead to substantial translational outcomes that will advance
the management of these diverse HNOC types. This has
been realized and a few studies have been devoted to
the identiﬁcation of site-speciﬁc microRNA signature for
HNOC, including a study by Wong et al. 2008, speciﬁc
microRNA proﬁles were deﬁned for the SCC of tongue [25],
one of the more aggressive type of HNOC in terms of
invasion, spread, and recurrence [106, 107].
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